Histocytological confirmation | Anticancer treatment | |||||
OR* | 95% CI | p Value | OR* | 95% CI | p Value | |
Male | 1 | – | – | 1 | – | – |
Female | 0.81 | 0.77 to 0.86 | <0.001 | 0.91 | 0.86 to 0.96 | 0.002 |
Age (years) | ||||||
<40 | 0.85 | 0.55 to 1.31 | 0.451 | 1.10 | 0.70 to 1.72 | 0.671 |
40–49 | 1.40 | 1.12 to 1.76 | 0.004 | 1.97 | 1.57 to 2.47 | <0.001 |
50–59 | 1.34 | 1.19 to 1.52 | <0.001 | 1.40 | 1.25 to 1.58 | <0.001 |
60–69 | 1 | – | - | 1 | – | - |
70–79 | 0.71 | 0.65 to 0.76 | <0.001 | 0.59 | 0.55 to 0.63 | <0.001 |
80–89 | 0.36 | 0.33 to 0.39 | <0.001 | 0.24 | 0.22 to 0.26 | <0.001 |
>90 | 0.12 | 0.10 to 0.15 | <0.001 | 0.07 | 0.05 to 0.10 | <0.001 |
Cancer stage | ||||||
IA | 1 | – | – | 1 | – | – |
IB | 1.47 | 1.23 to 1.75 | <0.001 | 1.29 | 1.07 to 1.56 | 0.007 |
IIA | 1.07 | 0.72 to 1.58 | 0.735 | 0.99 | 0.65 to 1.49 | 0.946 |
IIB | 1.65 | 1.34 to 2.02 | <0.001 | 1.06 | 0.86 to 1.30 | 0.585 |
IIIA | 1.66 | 1.40 to 1.98 | <0.001 | 1.01 | 0.85 to 1.22 | 0.876 |
IIIB | 1.92 | 1.65 to 2.25 | <0.001 | 0.85 | 0.72 to 1.00 | 0.049 |
IV | 1.38 | 1.20 to 1.59 | <0.001 | 0.59 | 0.51 to 0.68 | <0.001 |
Unknown | 0.87 | 0.75 to 1.00 | 0.055 | 0.52 | 0.44 to 0.60 | <0.001 |
Performance status | ||||||
0 | 1 | – | – | 1 | – | - |
1 | 0.93 | 0.83 to 1.04 | 0.205 | 0.84 | 0.76 to 0.94 | 0.002 |
2 | 0.47 | 0.42 to 0.53 | <0.001 | 0.34 | 0.30 to 0.38 | <0.001 |
3 | 0.20 | 0.18 to 0.23 | <0.001 | 0.10 | 0.09 to 0.11 | <0.001 |
4 | 0.10 | 0.09 to 0.12 | <0.001 | 0.03 | 0.02 to 0.04 | <0.001 |
Unknown | 0.43 | 0.38 to 0.48 | <0.001 | 0.31 | 0.28 to 0.34 | <0.001 |
Diagnosed comorbidity | 0.75 | 0.69 to 0.82 | <0.001 | 0.75 | 0.69 to 0.82 | <0.001 |
Histocytologically confirmed | – | – | – | 4.02 | 3.75 to 4.30 | <0.001 |
↵* Fully adjusted for all variables in the table.